GSK to Acquire Sierra Oncology for $1.9 Billion

GSK Acquires Elsie Biotechnologies for up to $50M

June 6, 2024

Biotechnology

GSK plc has completed the acquisition of Elsie Biotechnologies, a San Diego–based oligonucleotide-focused biotechnology company, for up to $50 million. The deal integrates Elsie's discovery, synthesis and delivery capabilities into GSK's oligonucleotide R&D platform to accelerate development of therapeutics for chronic hepatitis B, steatotic liver disease and other difficult-to-treat diseases.

GSK to Acquire IDRx in Up-to $1.15 Billion Deal

January 15, 2025

Biotechnology

GSK has entered into an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on precision therapeutics for GIST. The deal includes an upfront payment of $1 billion plus a potential additional $150 million success-based regulatory milestone payment.

Gilead Sciences Acquires Forty Seven for $4.9 Billion

March 2, 2020

Biotechnology

Gilead Sciences agreed to acquire clinical-stage immuno-oncology company Forty Seven for $95.50 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition adds Forty Seven's lead investigational antibody magrolimab to Gilead's oncology pipeline and is expected to close in Q2 2020 subject to customary approvals.

GSK to Acquire Aiolos Bio

January 9, 2024

Pharmaceuticals

GSK plc has entered an agreement to acquire Aiolos Bio, a clinical-stage biopharmaceutical company focused on unmet needs in respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in success-based regulatory milestone payments. The deal gives GSK access to Aiolos’ AIO-001, a long-acting anti-TSLP monoclonal antibody (phase II-ready) intended for adult asthma and potentially additional indications.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

Pfizer Acquires Global Blood Therapeutics (GBT) for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer entered into a definitive agreement to acquire Global Blood Therapeutics (GBT), paying $68.50 per share in cash for an enterprise value of about $5.4 billion. The deal adds GBT’s sickle cell disease portfolio, including Oxbryta (voxelotor), along with clinical pipeline assets such as GBT021601 (GBT601) and inclacumab.